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creativecommons.org/licenses/by-nc-nd/Abstract Background: Treatment options are limited for recurrent nasopharyngeal carci-
noma (NPC). We report results from a phase II study of CC-486 (oral azacitidine) in advanced
NPC.
Patients and methods: Patients with locally advanced or metastatic NPC and 1e2 prior treat-
ment regimens received CC-486 300 mg daily on days 1e14 of 21-day cycles until disease pro-
gression or unacceptable toxicity. The first 6 patients of Asian-Pacific Islander (API) ethnicity
received a reduced dose of 200 mg to preserve safety and tolerability; if well tolerated, subse-
quent API patients received CC-486 300 mg. The study could advance to stage 2 if > 4 patients
achieved a response. Co-primary end-points were overall response rate (ORR) and
progression-free survival (independent review). Key secondary end-points were overall sur-
vival and safety.
Results: Owing to faster-than-anticipated enrolment, 36 patients, including 13 of API
ethnicity, were enrolled; the median age was 54.0 years. Most patients were male (81%) and
had an Eastern Cooperative Oncology Group performance status  1 (97%). Among 25f Medical Oncology Institut Catala` d’Oncologia (ICO), Carretera del Canyet s/n, 08916, Badalona, Spain.
.net (R. Mesia).
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vival were 4.7 and 18.0 months, respectively. The most common grade III/IV treatment-
emergent adverse events were neutropenia (33%) and febrile neutropenia (11%). Twenty-one
posttreatment deaths, primarily due to progressive disease or disease complications, and 1
on-treatment death (epistaxis, unrelated to study drug) occurred. The study did not advance
to stage 2.
Conclusion: CC-486 did not show sufficient clinical activity to support further development as
monotherapy in this patient population. The safety profile of CC-486 in NPC was consistent
with that in other solid tumours.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nasopharyngeal carcinoma (NPC) is one of the most
common head and neck cancers [1,2]. The incidence of
NPC in most parts of the world is < 1 in 100,000;
however, it is more common in specific parts of the
world (eg, southern China and North Africa) and ethnic
groups (eg, Inuits in Alaska/Canada, Nagas in northern
India and Bidayuh in Borneo) [2e5]. Most patients have
advanced NPC at diagnosis [6,7]. The 5-year survival
rate (in the United States and Europe) is approximately
50%e60% [7,8]. Even with intensity-modulated radio-
therapy, patients develop local recurrence (z15%) and
distant metastasis (z30%) [9].
In phase II studies, first-line platinum-based doublets
demonstrated a median progression-free survival (PFS)
of approximately 7 months and overall survival (OS) of
12e28 months in metastatic NPC [10,11]. In a rando-
mised phase III study of recurrent/metastatic NPC,
gemcitabine plus cisplatin resulted in a significantly
longer median PFS (7.0 vs 5.6 months; P < 0.001) and
OS (29.1 vs 20.9 months; P Z 0.003; preliminary anal-
ysis) than fluorouracil plus cisplatin [12]. The National
Comprehensive Cancer Network guidelines recommend
gemcitabine plus cisplatin (category 1) as first-line
treatment for recurrent, unresectable or metastatic
NPC [13]. However, no standard of care exists for
advanced NPC in the second-line setting.
Epstein-Barr virus (EBV) infection, environmental
factors (eg, heavy alcohol/tobacco use, diet rich in salt-
cured meat), family history and mutations in epigenetic
modulators may play important roles in NPC patho-
genesis [9,14]. Aberrant DNA methylation and histone
modifications may contribute to NPC initiation and
progression [14e16]. Noncytotoxic gene
expressionemodulating agents (eg, azacitidine) repre-
sent an emerging approach to treating advanced NPC
[9,17]. CC-486 (oral azacitidine) is a cytosine nucleoside
analogue that irreversibly binds to DNA methyl-
transferases, leading to DNA hypomethylation and
potential re-expression of methylation-silenced genes.
CC-486 is hypothesised to result in immune-mediated
antitumour effects in patients with NPC. Anexploratory analysis of a phase I study suggested clinical
activity of CC-486 monotherapy in NPC: of 8 patients, 3
had a partial response (PR), 4 had stable disease (SD)
and 1 had disease progression [18]. This phase II study
assessed the efficacy and safety of CC-486 monotherapy
in previously treated patients with advanced NPC.2. Methods
2.1. Study oversight
The study was conducted in accordance with the Inter-
national Conference on Harmonisation E6 and Decla-
ration of Helsinki. The protocol, amendments and
informed consent forms were approved by the institu-
tional review board or ethics committee of each study
site before study initiation.
2.2. Study population
Patients (aged 18 years) with locally advanced or
metastatic and undifferentiated/poorly differentiated
NPC and disease progression with 1e2 prior treatment
regimens, including a platinum-based chemotherapy,
were eligible. Key exclusion criteria were prior treatment
with a hypomethylating agent, presence/history of brain
metastasis, history of inflammatory bowel disease or any
gastrointestinal disorder/defect and active bleeding. An
Eastern Cooperative Oncology Group performance
status (ECOG PS) 2, measurable disease per Response
Evaluation Criteria in Solid Tumors (RECIST), version
1.1, and adequate organ/bone marrow function were
required. The full list of inclusion/exclusion criteria is
included in Supplementary Methods.
2.3. Study design, treatments and end-points
This multicentre, single-arm, open-label, phase II study
(NCT02269943) was conducted at 17 sites in Canada,
France, Greece, Italy, Singapore, Spain, Tunisia,
Taiwan and the United States. The study used Simon’s
optimal 2-stage design (Supplementary Fig. S1) [19].
Fig. 1. Patient disposition. aAdditional details, including the rea-
sons for death, are provided in Table 3 in the manuscript.
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orally on days 1e14 of 21-day cycles until disease pro-
gression or unacceptable toxicity. In a phase I study, 4
of 5 Japanese patients treated with CC-486 300 mg qd
for 21 days of a 28-day cycle experienced grade IIIIV
neutropenia (unpublished data). Therefore, to preserve
safety in patients of Asian-Pacific Islander (API)
ethnicity in the present study, the first 6 safety-evaluable
API patients received CC-486 200 mg qd. Subsequent
API patients received 300 mg qd if 200 mg was well
tolerated (according to dose-limiting toxicities,
described in Supplementary Methods). Patients could
receive 1 dose reduction for adverse events (AEs) and
were allowed dose interruptions of 7 days without
requiring dose reduction.
The co-primary end-points were independently
assessed overall response rate (ORR) and PFS; the deci-
sion to continue to stage 2 was based on ORR. The sec-
ondary end-points were disease control rate (DCR), OS,
safety and pharmacokinetics. The exploratory objective
was to generate predictive biomarker hypotheses based
on tumour evaluations at baseline and cycle 2, day 1.
2.4. Study assessments
ORR was defined as complete response (CR) plus PR
(confirmed 4 weeks after response criteria per RECIST
1.1 were first met); DCR was defined as ORR plus SD
for 16 weeks from the first treatment per RECIST 1.1
criteria. ORR and DCR point estimates and 2-sided
90% confidence intervals (CIs) were reported using the
Clopper-Pearson method. PFS and OS were estimated
using the KaplaneMeier method; medians and 2-sided
90% CIs were reported. Baseline levels of serum
EBV-DNA were measured centrally (Seattle Children’s
Laboratory, Seattle, WA), using real-time quantitative
polymerase chain reaction.
Safety data were reported as descriptive statistics.
AEs were coded using the Medical Dictionary for
Regulatory Activities, version 19.0, and severity was
graded according to the Common Terminology Criteria
for Adverse Events, version 4.0 (additional details in
Supplementary Methods).
2.5. Statistical analyses
The sample size was determined based on having a
sufficient number of patients in the efficacy-evaluable
population achieving ORR >20% or median PFS >5
months. In stage 1, 17 efficacy-evaluable patients
(defined in Supplementary Methods) were to be
enrolled, and if > 4 responded (prespecified criterion;
best response of CR/PR), 34 additional patients were to
be enrolled in stage 2. Overall, 14 responses or median
PFS >5 months was considered to render the study
positive. This provided a power of 85% when the true
ORR was 40% and, after stage 2, a power of 80% or 60%when the true median PFS was approximately 8 or 7
months, respectively.
3. Results
3.1. Patient disposition
Overall, 36 patients were enrolled in stage 1 between
February and September 2015 (Fig. 1); the last patient’s
last visit was in April 2017. The number of patients
enrolled in stage 1 exceeded what was planned because of
faster-than-anticipated enrolment; patients who signed
the informed consent formandmet eligibility criteriawere
permitted to enter the study. Of 36 enrolled patients, 25
were efficacy evaluable. Three patients (300-mg cohort)
were excluded because they did not receive 2 CC-486
cycles, and 8 (7 in the 300-mg cohort and 1 in the 200-
mg cohort) were excluded because they received 2 CC-
486 cycles but discontinued before completing 4 cycles
for reasons other than progressive disease, including
toxicities and consentwithdrawal. Five efficacy-evaluable
API patients received CC-486 200 mg and 20 (6 API and
14 white) received CC-486 300 mg. Because no dose-
limiting toxicities were reported in API patients who
received CC-486 200 mg during cycle 1, subsequent API
patients received the CC-486 300-mg dose. The median
follow-up for survival was 20.4 months.
3.2. Demographic and baseline clinical characteristics
The median age of patients was 54.0 years. Most patients
weremale (80.6%), had anECOGPS 1 (97.2%) and had
Table 1
Demographic and baseline characteristics (enrolled population).
Characteristic Enrolled patients
(N Z 36)
Age, median (range), yearsa 54.0 (24e71)
<65, n (%) 29 (80.6)
<30b 1 (2.8)
30 to <65b 28 (77.8)
65 to <75, n (%) 7 (19.4)
75, n (%) 0
Male, n (%) 29 (80.6)
Race, n (%)
White 23 (63.9)
API 13 (36.1)
BMI, median (range), kg/m2 23.7 (16.3e31.0)c
Patients receiving 300 mg 23.2 (16.3e31.0)
API patients receiving 200 mg 24.7 (17.4e30.5)
ECOG PS, n (%)d
0 15 (41.7)
1 20 (55.6)
2 1 (2.8)
EBV-DNA levels, median (range),
copies/mL
1146.5 (200e506,790)
EBV-DNA interpretation, n (%)e
Negative (<200 copies/mL)f 10 (27.8)
White 5 (21.7)
API 5 (38.5)
Positive (200 copies/mL)f 20 (55.6)
White 12 (52.2)
API 8 (61.5)
Missing 6 (16.7)
White 6 (26.1)
API 0
Current cancer site, n (%)
Metastatic 28 (77.8)
Locally advanced 8 (22.2)
Cancer diagnosis, n (%)
Undifferentiated 23 (63.9)
Poorly differentiated 11 (30.6)
Nonkeratinizing, undifferentiated 2 (5.6)
Prior anticancer therapy, n (%)
Any anticancer treatment 36 (100.0)
Radiotherapy 28 (77.8)
Surgery 10 (27.8)
Systemic therapyg 35 (97.2)
Cisplatin 30 (83.3)
Fluorouracil 21 (58.3)
Gemcitabine 17 (47.2)
Carboplatin 14 (38.9)
Docetaxel 11 (30.6)
Prior lines of systemic therapy,
median (range)
2.0 (1.0e6.0)
Time from end of prior systemic
anticancer therapy to first dose of
CC-486, median (range), months
5.1 (0.9e57.3)
API, Asian-Pacific Islander; BMI, body mass index; EBV, Epstein-
Barr virus; ECOG PS, Eastern Cooperative Oncology Group perfor-
mance status.
a Age Z maximum integer  (date of informed consent  date of
birth þ 1)/365.25.
b This age group was not prespecified and is presented because of
clinical relevance.
c nZ 34; 2 patients in the 300-mg cohort hadmissing baselineBMIdata.
d Last assessment before the first dose.
e Measured by real-time polymerase chain reaction in serum using
the last measurement before the first dose administration.
f 200 copies/mL defined the limit of quantitative detection.
g Breakdown is for the most frequently used systemic therapy (25%
of patients). A patient could have received >1 specific prior systemic
therapy either in combination or sequentially.
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mately one-third of patients (13/36)were ofAPI ethnicity.
3.3. Efficacy
The independently assessed ORR was 12.0% (90% CI,
3.4e28.2; 3 patients [300-mg cohort] achieved PR); the
DCRwas 52.0% (10 patients [7 in the 300-mg cohort and 3
in the 200-mg cohort] had SD) (Table 2). In the 300-mg
cohort, the ORR/DCR was 17%/50% (1 PR, 2 SDs) in
API patients and 14%/50% (2 PRs, 5 SDs) in white pa-
tients. In the 200-mg cohort, the ORR/DCRwas 0%/60%
(3 SDs). The investigator-assessed ORR (16.0% [90% CI,
5.7e33.0]; 4 PRs; Table 2) was consistent with the inde-
pendently reviewed ORR. Fig. 2 shows the nadir percent
change from baseline in the sum of the longest diameters
of target lesions for individual patients.
The median PFS by independent review was 4.7
months (90% CI, 3.1e7.3; Table 2). The estimated 1-
year PFS rate was 25.7% (90% CI, 12.6e41.1). The
median PFS by investigator review was 6.4 months (90%
CI, 4.7e10.1); the estimated 1-year PFS rate was 29.5%
(90% CI, 15.4e45.0). The median OS was 18.0 months
(90% CI, 14.8enot available). The estimated 1-year OS
rate was 80.0% (90% CI, 62.7e89.9).
To look for any potential link between response and
baseline EBV-DNA levels, we examined the data for 21
of 25 efficacy-evaluable patients with available EBV-
DNA levels. Among 10 patients with EBV-DNA levels
below the limit of quantification (ie, < 200 copies/mL), 3
patients (30%) had a partial response, 5 (50%) had stable
disease and 2 (20%) had disease progression. Among 11
patients with detectable levels of EBV-DNA (200
copies/mL), 6 patients (55%) had stable disease and 5
(45%) had disease progression. The median (range)
EBV-DNA level was 10,257 (236e506,790) copies/mL,
and no clear pattern was observed between increasing
levels of baseline EBV-DNA and response to CC-486.
3.4. Pharmacokinetics
The pharmacokinetic properties of CC-486 were studied
in API patients. The plasma concentration vs time
profiles showed a relatively rapid absorption phase in
both the 200-mg and 300-mg cohorts (Supplementary
Fig. S2). In both cohorts, the median time to
maximum plasma concentration was approximately 1 h,
and the terminal elimination phase began approximately
2 h after dosing. The CC-486 area under the curve
(AUC) and peak concentration (Cmax) were comparable
in the 2 cohorts (Supplementary Table S1).
3.5. Treatment exposure, dose reductions and dose
interruptions
The median treatment duration was 4.7 months, and the
median number of cycles received was 7 (Supplementary
Table 2
Efficacy outcomes.
Parameter Efficacy-evaluable patients
(n Z 25)
Independent
review
Investigator
review
Best confirmed response, n (%)
CR 0 0
PR 3 (12.0) 4 (16.0)
SD  16 weeks 10 (40.0) 14 (56.0)
PD 7 (28.0) 4 (16.0)
ORR (90% CI), % 12.0 (3.4e28.2) 16.0 (5.7e33.0)
DCR (90% CI), % 52.0 (34.1e69.5) 72.0 (53.8e86.1)
PFS
Deaths or disease progression,
n (%)
20 (80.0) 23 (92.0)
Median (90% CI), months 4.7 (3.1e7.3) 6.4 (4.7e10.1)
OS
Deaths, n (%) 13 (52.0)
Median (90% CI), months 18.0 (14.8eNA)
CI, confidence interval; CR, complete response; DCR, disease control
rate; NA, not available; ORR, overall response rate; OS, overall sur-
vival; PD, progressive disease; PFS, progression-free survival; PR,
partial response; SD, stable disease.
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100.2% (range, 25.0%e150.0%), and the median cumu-
lative dose was 21.2 g.
Fourteen patients (38.9%), including 5 in the 200-mg
cohort (83.3%), required a CC-486 dose reduction.
Sixteen patients (44.4%), including 3 in the 200-mg
cohort (50.0%), had 1 dose interruption. Neutropenia
was the most common treatment-emergent adverse
event (TEAE) leading to CC-486 dose reduction, inter-
ruption or discontinuation (Supplementary Table S3).
3.6. Subsequent anticancer therapy
Thirteen efficacy-evaluable patients (52.0%) received
systemic anticancer therapy after discontinuing treat-
ment (Supplementary Table S4).Fig. 2. Nadir percent change from baseline in sum of longest3.7. Safety
All patients experienced 1 TEAE (Table 3). The most
common grade III/IV TEAEs (in >2 patients) were
neutropenia (33.3%), febrile neutropenia (11.1%),
leukopenia (8.3%) and vomiting (8.3%). Sixteen patients
(44.4%) experienced 1 serious TEAE. Twenty-one
posttreatment deaths (200-mg group, n Z 4; 300-mg
group, n Z 17) and 1 on-treatment death (300-mg
group) occurred. In the 200-mg group, deaths were
attributed to progressive disease or disease complica-
tions (nZ 2), AE (septic shock considered to be related
to CC-486; n Z 1), or other cause (n Z 1). In the 300-
mg group, the posttreatment deaths were attributed to
progressive disease or disease complications (nZ 16) or
unknown cause (n Z 1). The only on-treatment death
(300-mg group) was attributed to epistaxis, considered
to be unrelated to CC-486.
4. Discussion
This study did not demonstrate sufficient efficacy of CC-
486 to warrant advancement to stage 2. Although the
response rates were low, 19 of 25 efficacy-evaluable
patients (76.0%) showed some degree of response. The
DCR of 52% was better than expected for this heavily
pretreated patient population with primarily metastatic
NPC. These observations raise the possibility that CC-
486 acts mainly via disease stabilisation. CC-486 was
generally well tolerated, with no new safety signals
[20,21]. Although the AUC and Cmax in the 200-mg and
300-mg cohorts were comparable, the relatively small
sample size and large between-patient variability pre-
cluded a definitive conclusion.
Combining azacitidine with agents such as valproic
acid and all-trans retinoic acid and growth factors has
shown promising activity in acute myeloid leukaemia
and myelodysplastic syndrome [22,23]. In NPC pre-
clinical studies, CC-486 has shown the potential todiameters of target lesions (efficacy-evaluable population).
Table 3
Treatment-emergent adverse events (safety population)a.
Patients, n (%) Safety population
(N Z 36)
Any-grade TEAEs
Patients with 1 TEAE 36 (100.0)
Most common TEAEs (30% incidence)
Vomiting 26 (72.2)
Nausea 24 (66.7)
Diarrhoea 13 (36.1)
Neutropenia 13 (36.1)
Constipation 11 (30.6)
Grade III/IV TEAEs
Patients with 1 grade III/IV TEAE 26 (72.2)
Most common grade III/IV TEAEs (in >2 patients)
Neutropenia 12 (33.3)
Febrile neutropenia 4 (11.1)
Leucopenia 3 (8.3)
Vomiting 3 (8.3)
Serious TEAEs
Patients with 1 serious TEAE 16 (44.4)
Most common serious TEAEs (in 2 patients)
Febrile neutropenia 4 (11.1)
Dysphagia 2 (5.6)
Vomiting 2 (5.6)
Pyrexia 2 (5.6)
Neutrophil count decreased 2 (5.6)
Cerebrovascular accident 2 (5.6)
Summary of deaths
Deaths 22 (61.1)
On treatment 1 (2.8)
Due to AE (epistaxis) 1 (2.8)
Posttreatment 21 (58.3)
Due to NPC or its complication 18 (50.0)
Cause unknown 1 (2.8)
Due to AE (septic shock) 1 (2.8)
Due to other cause 1 (2.8)
AE, adverse event; NPC, nasopharyngeal carcinoma; TEAE,
treatment-emergent adverse event.
a TEAEs were defined as any AEs that began or worsened on or after
the start of CC-486 through 28 days after the last dose. In addition,
any AE with an onset >28 days after the last dose assessed by the
investigator as related to CC-486 was considered a TEAE. Severity of
an AE was graded using Common Terminology Criteria for Adverse
Events (CTCAE), version 4.0. If multiple toxicity grades were associ-
ated with an AE, the maximum severity was used. For AEs not
described in the CTCAE criteria, severity was assessed by the inves-
tigator as mild (grade I), moderate (grade II), severe (grade III), life-
threatening (grade IV) or death (grade V).
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mechanism of action of CC-486 suggests the possibility
of combination with similar drugs and immunotherapies
for the treatment of NPC. Hypermethylation is associ-
ated with poor survival outcomes in patients with NPC
and may be a useful prognostic biomarker [26]. Azaci-
tidine is thought to reactivate the host immune response
through demethylation of silenced genes, especially in
EBV-associated tumours, in which it reactivates silenced
immunodominant antigens in infected cells. This could
create a more favourable microenvironment for immu-
notherapies by enhancing tumour-specific antigen pre-
sentation, thus expanding the primary and adaptiveimmune responses [27]. A limitation of this study was
that relatively few tumour biopsy samples were
collected, which precluded any biomarker and correla-
tion analyses. In the absence of any biomarker data, it is
unclear whether the observed activity was a result of
direct action of CC-486 or mediated by a reactivated
host immune response. The lack of detailed biomarker
data also precluded meaningful interpretations
regarding any correlation between change in EBV-DNA
and clinical response.
The role of immunotherapies targeting the tumour
(cytotoxic T lymphocytes) or the host has been studied in
recurrent/metastatic NPC [28e31]. In studies of the im-
mune checkpoint inhibitors nivolumab and pem-
brolizumab, an ORR of 20%e26% and a 1-year OS of
59%e63% in mostly pretreated patients was reported
[30,31]. In phase I trials, camrelizumab, a programmed
cell death protein 1 inhibitor, alone (second line) or with
cisplatin/gemcitabine (first line) showed a manageable
safety profile and promising antitumour activity in pa-
tients with recurrent/metastatic NPC [32]. The promising
results observed with immune checkpoint inhibitors,
along with the CC-486mechanism of action and response
data reported here, provoke the interesting speculation
that their combination may exhibit synergistic activity.
Future studies could determine whether treating earlier
stages of NPC with CC-486 monotherapy or advanced
stages with CC-486 combined with other drugs, including
immunotherapy, will produce more desirable outcomes.
5. Conclusion
This was a nonrandomised study with a relatively small
sample size. CC-486 monotherapy at the selected dose
did not show sufficient clinical activity in patients with
advanced NPC to warrant further clinical development
in this indication. In the first 6 API patients who were
assessed for safety and tolerability with CC-486 200 mg,
no new safety signals were noted. The safety profile of
CC-486 in NPC was consistent with that in other solid
tumours and with the safety profile of injectable azaci-
tidine. The safety and response data for CC-486 re-
ported here support consideration of combination with
other treatments, including immunotherapy.
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